Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 53 out of 100. Inflammation and the immune system

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Recent studies show that Alzheimer's disease (AD) has many common links with conditions associated with insulin resistance, including neuroinflammation, impaired insulin signaling, oxidative stress, mitochondrial dysfunction and metabolic syndrome. The authors conducted an electronic search for publications in the PubMed/MEDLINE and Google Scholar databases using the keywords "amyloid beta", "Alzheimer type-3-diabetes", "intranasal insulin", "metformin", "type 2 diabetes mellitus", "incretins" and "PPARy agonists». A systematic literature search was conducted among studies published between 2005 and 2022. The authors used the following inclusion criteria: 1) Subjects who received therapy for AD and/or DM2, if the expected result concerned the risk of cognitive decline or the development of dementia; 2) The age of the study participants is > 50 years; 3) The type of studies included in this review were randomized clinical trials, population-based observational studies or case-control studies, prospective cohort studies, as well as reviews and meta-analyses; 4) The included articles were written in English. In recent years, there has been considerable interest in identifying the mechanisms of action of antidiabetic drugs and their potential use in AD. Human studies involving patients with mild cognitive impairment and Alzheimer's disease have shown that the administration of certain antidiabetic drugs, such as intranasal insulin, metformin, incretins and thiazolidinediones, can improve cognitive function and memory. The purpose of this study is to evaluate the effectiveness of antidiabetic drugs in the treatment of AD. According to the results of the study, metformin, intranasal insulin, thiazolidinediones and incretins showed a positive effect both in humans and in animal models. Recent studies show that thiazolidinediones can activate pathways in the brain that are regulated by IGF-1; however, rosiglitazone may pose a significant risk of side effects. The results of clinical studies on the use of metformin in AD are limited and contradictory.

What this study adds

Evidence grade: High

This is a pooled review. This review looks at diabetes drugs as possible Alzheimer's treatments, since the two conditions share problems such as insulin resistance and inflammation. Metformin, intranasal insulin, thiazolidinediones and incretins showed positive effects in both people and animal models, but rosiglitazone may carry a significant risk of side effects.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Ishmuratova, A. N., Abramov, M. A., Kuznetsov, K. O., Ivanyuta, M. V., Shakirova, Z. F., Kitapova, A. I., et al. (2023). [The role of antidiabetic drugs in the treatment of Alzheimer's disease: systematic review]. Problemy endokrinologii. https://doi.org/10.14341/probl13183

Vancouver

Ishmuratova AN, Abramov MA, Kuznetsov KO, Ivanyuta MV, Shakirova ZF, Kitapova AI, et al. [The role of antidiabetic drugs in the treatment of Alzheimer's disease: systematic review]. Problemy endokrinologii. 2023. doi:10.14341/probl13183. PMID: 37968954.

BibTeX

@article{ishmuratova2023-37968954,
  author  = {Ishmuratova, A. N. and Abramov, M. A. and Kuznetsov, K. O. and Ivanyuta, M. V. and Shakirova, Z. F. and Kitapova, A. I. and Usmonov, M. D. and Chernousova, L. M. and others},
  title   = {{[The role of antidiabetic drugs in the treatment of Alzheimer's disease: systematic review]}},
  journal = {Problemy endokrinologii},
  year    = {2023},
  doi     = {10.14341/probl13183},
  pmid    = {37968954},
  url     = {https://doi.org/10.14341/probl13183}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This review looks at diabetes drugs as possible Alzheimer's treatments, since the two conditions share problems such as insulin resistance and inflammation. Metformin, intranasal insulin, thiazolidinediones and incretins showed positive effects in both people and animal models, but rosiglitazone may carry a significant risk of side effects. Clinical results for metformin in Alzheimer's were limited and contradictory, so the case is not settled.

Study details

How this study scored 53/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record left out, no data; Study design 12 of 12; Strength of evidence 5 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 2 of 7; Citations per year 1 of 5; Impact for its field and year 1 of 6; Cited by studies here 1 of 6; Still being cited 1 of 4; Senior author's track record left out, no data; Institution's track record 0 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. 49 of the 92 points it could be judged on, which is 53 of 100. Total 53 of 100.49 of the 92 points we could judge = 53 of 100

Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies. Scored zero for sample size, effect reported and studied in people because the record does not state it. We have no data on journal's citation record and senior author's track record, so those were left out: it earned 49 of the 92 points we could judge it on, which is 53 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Problemy endokrinologii)
Journal's citation record — / 4 No journal record from OpenAlex — left out of this score
Study design 12 / 12 A meta-analysis pooling many studies
Strength of evidence 5 / 5 Rated “high” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2023 — within 6 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited 2 / 7 Cited 8 times (OpenAlex, 2026-10-10)
Citations per year 1 / 5 1.6 citations a year over 5 year(s) since 2023
Impact for its field and year 1 / 6 Cited 0.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 1 / 4 Cited 8 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Kamila Yakupova holds only 4 work(s), too few to judge a track record — left out of this score
Institution's track record 0 / 3 Pirogov Russian National Research Medical University: institution h-index 190 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 37968954)
Free to read 2 / 2 Free to read
Points 49 / 92 Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 49 of the 92 points we could judge it on is 53 out of 100.
Total 53 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Inflammation and the immune system from nearby years

Also in Inflammation and the immune system

141 studies in the library are filed under Inflammation and the immune system with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Inflammation and the immune system hub.

Similar studies

More on Inflammation and the immune system

See all studies in Inflammation and the immune system →